ATE382633T1 - Reagenzien zur zellselektion und verfahren zur anwendung - Google Patents

Reagenzien zur zellselektion und verfahren zur anwendung

Info

Publication number
ATE382633T1
ATE382633T1 AT01941591T AT01941591T ATE382633T1 AT E382633 T1 ATE382633 T1 AT E382633T1 AT 01941591 T AT01941591 T AT 01941591T AT 01941591 T AT01941591 T AT 01941591T AT E382633 T1 ATE382633 T1 AT E382633T1
Authority
AT
Austria
Prior art keywords
peptide
cell
ligand
provides
conjugate
Prior art date
Application number
AT01941591T
Other languages
English (en)
Inventor
Andrew Schaeffer
Janet Tseng-Law
Jeffrey Thornton
Epps Dennis Van
Original Assignee
Baxter Healthcare Sa
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare Sa, Baxter Int filed Critical Baxter Healthcare Sa
Application granted granted Critical
Publication of ATE382633T1 publication Critical patent/ATE382633T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
AT01941591T 2000-05-23 2001-05-23 Reagenzien zur zellselektion und verfahren zur anwendung ATE382633T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57878400A 2000-05-23 2000-05-23
US65946900A 2000-09-11 2000-09-11

Publications (1)

Publication Number Publication Date
ATE382633T1 true ATE382633T1 (de) 2008-01-15

Family

ID=27077582

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01941591T ATE382633T1 (de) 2000-05-23 2001-05-23 Reagenzien zur zellselektion und verfahren zur anwendung

Country Status (8)

Country Link
US (1) US20030119070A1 (de)
EP (1) EP1317476B1 (de)
JP (1) JP2004501110A (de)
AT (1) ATE382633T1 (de)
AU (2) AU2001274931B2 (de)
DE (1) DE60132221T2 (de)
MX (1) MXPA02011587A (de)
WO (1) WO2001090153A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030219445A1 (en) * 2000-05-23 2003-11-27 Nexell Therapeutics, Inc. Reagents for cell selection and methods of use
DE10256042B4 (de) * 2002-11-30 2006-06-08 Universität Potsdam Verfahren zur Selektion von Zellen, die spezifisch bindende Moleküle produzieren
DE10310082A1 (de) * 2003-03-07 2004-09-16 Ktb Tumorforschungsgesellschaft Mbh Protein-bindende Doxorubicin-Peptid-Derivate
US9140707B2 (en) * 2007-08-10 2015-09-22 University Of Louisville Research Foundation, Inc. Sensors and methods for detecting diseases caused by a single point mutation
WO2009079922A1 (en) * 2007-12-13 2009-07-02 Shanghai Guojian Bio-Tech Institute Humanized anti-cd34 monoclonal antibody, the preparation and uses thereof
US20100279322A1 (en) * 2009-05-04 2010-11-04 Creatv Microtech, Inc. Direct detection of intracellular fluorescently tagged cells in solution
CN105277703A (zh) * 2014-07-23 2016-01-27 江苏维赛科技生物发展有限公司 一种快速检测农作物中代森环含量的试剂盒
KR101697473B1 (ko) * 2014-11-26 2017-01-18 주식회사 녹십자랩셀 T 세포를 이용한 자연살해세포의 배양방법
EP3633029A4 (de) 2017-05-26 2021-06-09 Green Cross Lab Cell Corporation Verfahren zur entwicklung einer natürlichen killerzelle unter verwendung einer t-zelle
EP3653648A4 (de) * 2017-07-11 2020-06-03 National University Corporation University Of Toyama Mit polymeren beschichtetes substrat zur selektiven trennung von zellen oder zur zellkultivierung
WO2019033043A2 (en) 2017-08-11 2019-02-14 Genentech, Inc. ANTI-CD8 ANTIBODIES AND USES THEREOF
JP7179986B2 (ja) 2018-11-14 2022-11-29 グリーン クロス ラボ セル コーポレーション 形質転換されたｔ細胞を用いた臍帯血由来のナチュラルキラー細胞の培養方法
WO2021010886A1 (en) * 2019-07-12 2021-01-21 Louise Rydén Innovation Ab A portable ecg device and an ecg system comprising the portable ecg device
AU2021213439B2 (en) * 2020-01-31 2023-01-05 Cell.Copedia GmbH Methods of isolating a biological entity

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4988621A (en) * 1985-05-24 1991-01-29 La Jolla Cancer Research Foundation Peptides in cell detachment and aggregation
US5262334A (en) * 1986-01-30 1993-11-16 Fred Hutchinson Cancer Research Center Method for immunoselection of cells using avidin and biotin
US5536475A (en) * 1988-10-11 1996-07-16 Baxter International Inc. Apparatus for magnetic cell separation
GB8916859D0 (en) * 1989-07-24 1989-09-06 Dynal As Hapten linking
US5646001A (en) * 1991-03-25 1997-07-08 Immunivest Corporation Affinity-binding separation and release of one or more selected subset of biological entities from a mixed population thereof
AU678179B2 (en) * 1992-07-28 1997-05-22 Steven Kessler Methods for positive immunoselection of stem cells
AU7832094A (en) * 1993-09-08 1995-03-27 Baxter International Inc. Biotin-analog conjugated antibodies for positive cell selection and release
US6017719A (en) * 1994-06-14 2000-01-25 Nexell Therapeutics, Inc. Positive and positive/negative cell selection mediated by peptide release
IL114149A0 (en) * 1995-06-14 1995-10-31 Yeda Res & Dev Modified avidin and streptavidin molecules and use thereof
DE19641876B4 (de) * 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
US5985658A (en) * 1997-11-14 1999-11-16 Health Research Incorporated Calmodulin-based cell separation technique
ATE480625T1 (de) * 1997-11-21 2010-09-15 Merck Serono Biodevelopment Äusseres membranpolypeptid von chlamydia pneumoniae sowie fragmente davon und deren verwendung, insbesondere zur diagnose, prävention und behandlung einer infektion
US6395890B1 (en) * 1998-02-20 2002-05-28 Zymogenetics, Inc. Nucleic acids encoding connective tissue growth factor homologs
WO1999061588A1 (en) * 1998-05-22 1999-12-02 Osiris Therapeutics, Inc. Production of megakaryocytes by co-culturing human mesenchymal stem cells with cd34+ cells
WO1999061587A1 (en) * 1998-05-29 1999-12-02 Osiris Therapeutics, Inc. Human cd45+ and/or fibroblast + mesenchymal stem cells
CA2365639C (en) * 1999-03-12 2013-05-14 Ortho-Mcneil Pharmaceutical, Inc. Method of isolating cd8+ cells, and related hybridoma cells, antibodies and polypeptides
US6184011B1 (en) * 1999-03-22 2001-02-06 Cbd Technologies, Ltd Method of releasing solid matrix affinity adsorbed particulates
US20030219445A1 (en) * 2000-05-23 2003-11-27 Nexell Therapeutics, Inc. Reagents for cell selection and methods of use
US7097835B2 (en) * 2001-07-18 2006-08-29 The Regents Of The University Of California Immunoselective targeting agents and methods of use thereof

Also Published As

Publication number Publication date
US20030119070A1 (en) 2003-06-26
WO2001090153A3 (en) 2003-03-20
AU7493101A (en) 2001-12-03
EP1317476A2 (de) 2003-06-11
DE60132221D1 (de) 2008-02-14
WO2001090153A8 (en) 2002-03-28
DE60132221T2 (de) 2009-01-02
JP2004501110A (ja) 2004-01-15
WO2001090153A2 (en) 2001-11-29
EP1317476B1 (de) 2008-01-02
MXPA02011587A (es) 2004-07-30
AU2001274931B2 (en) 2006-03-30

Similar Documents

Publication Publication Date Title
DE60132221D1 (de) Reagenzien zur zellselektion und verfahren zur anwendung
ATE528648T1 (de) Verfahren zum nachweis antikörper-herstellender zellen
DE69917051D1 (de) "flow-zytometrischer" vollblut- dendritzelle- immunfunctiontest
GB0001450D0 (en) Cell isolation method
AU3260299A (en) Immunoassays involving surface enhanced raman scattering
ATE185424T1 (de) Differentielle bindungsaffinitäten und darauf beruhende dissoziationstestverfahren
IL146660A0 (en) Method for separating cells using immunorosettes
WO2003065002A3 (en) Rapid lateral flow assay for determining exposure to mycobacterium tuberculosis and other mycobacteria
DE69731977D1 (de) Spezifische antikörper für dendritische zellen
AU2002222117A1 (en) Signal enhancement system with multiple labelled-moieties
DE69928507D1 (de) Festphasenverfahren und testsatz zur antigen- und antikörperprüfung in der blutgruppen-serologie
AU2707597A (en) Method of assay
ATE274187T1 (de) Marker für unfruchtbarkeit und/oder - fruchtbarkeit bei männern
WO2001092877A3 (en) Method of identifying and/or isolating stem cells
WO2001075449A1 (fr) Technique d'investigation du cancer par epreuve biologique d'un autoanticorps contre mdm2 et reactif
SE0301058D0 (sv) Method and kit for cell analyte assay
AU9497998A (en) Method for detecting antibodies in a sample
CA2440399A1 (en) Epitope testing using hla
ATE372514T1 (de) Gel für elektrophorese
WO2002090989A3 (de) Verfahren zum nachweis von blutzell-antigenen und gegen diese gerichtete antikörper
SE0002835D0 (sv) Method and kit for production of monoclonal antibodies
NO20052553L (no) Cobalaminanalyse.
DK1057021T3 (da) Fremgangsmåde til måling af totalanalyt
EP1188060A4 (de) Verfahren und apparatur zum präsentieren von daten von thrombose- und haemostaseassays
WO2003098212A3 (en) Method of isolating an endotehelial cell and method of donor specific crossmatching

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties